Identification of the metabolites of lesogaberan using linear trap quadrupole orbitrap mass spectrometry and hydrophilic interaction liquid chromatography

References

• Boeckxstaens GE, Beaumont H, Mertens V, Denison H, Ruth M, Adler J, Silberg DG, Sifrim D. (2010a). Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 139:409–417.
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Rydholm H, Lei A, Adler J, Ruth M. (2010b). Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther 31:1208–1217.
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Beaumont H, Hatlebakk JG, Silberg DG, Björck K, Karlsson M, Denison H. (2011). A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: A randomised placebo-controlled trial. Gut 60:1182–1188.
   PubMed Web of Science ®Google Scholar
• Chirita RI, West C, Finaru AL, Elfakir C. (2010). Approach to hydrophilic interaction chromatography column selection: Application to neurotransmitters analysis. J Chromatogr A 1217:3091–3104.
   PubMed Web of Science ®Google Scholar
• Cioffi U, Rosso L, De Simone M. (1999). Gastroesophageal reflux disease. Pathogenesis, symptoms and complications. Minerva Gastroenterol Dietol 45:43–49.
   Google Scholar
• Clift MD, Ji H, Deniau GP, O’Hagan D, Silverman RB. (2007). Enantiomers of 4-amino-3-fluorobutanoic acid as substrates for γ-aminobutyric acid aminotransferase. Conformational probes for GABA binding. Biochemistry 46:13819–13828.
   Google Scholar
• Cooke BR, Bligh SW, Cybulski ZR, Ioannides C, Hall M. (2012). Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes. Drug Metab Dispos 40:70–75.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, Smith DA. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357–368.
   PubMed Web of Science ®Google Scholar
• Dejaegher B, Vander Heyden Y. (2010). HILIC methods in pharmaceutical analysis. J Sep Sci 33:698–715.
   PubMed Web of Science ®Google Scholar
• Dent J, El-Serag HB, Wallander MA, Johansson S. (2005). Epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 54:710–717.
   PubMed Web of Science ®Google Scholar
• El-Serag H, Becher A, Jones R. (2010). Systematic review: Persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 32:720–737.
   PubMed Web of Science ®Google Scholar
• Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. (2010). Methodologies for investigating drug metabolism at the early drug discovery stage: Prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab 11:678–685.
   PubMed Web of Science ®Google Scholar
• FDA. (2008). Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0065-GDL.pdf. Accessed on: 5 March 2012.
   Google Scholar
• Fountain KJ, Xu J, Diehl DM, Morrison D. (2010). Influence of stationary phase chemistry and mobile-phase composition on retention, selectivity, and MS response in hydrophilic interaction chromatography. J Sep Sci 33:740–751.
   Google Scholar
• Hsieh Y. (2010). Hydrophilic interaction liquid chromatography-tandem mass spectrometry for drug development. Curr Drug Discov Technol 7:223–231.
   PubMedGoogle Scholar
• Humm A, Fritsche E, Steinbacher S, Huber R. (1997). Crystal structure and mechanism of human L-arginine:glycine amidinotransferase: A mitochondrial enzyme involved in creatine biosynthesis. EMBO J 16:3373–3385.
   Google Scholar
• Ikegami T, Tomomatsu K, Takubo H, Horie K, Tanaka N. (2008). Separation efficiencies in hydrophilic interaction chromatography. J Chromatogr A 1184:474–503.
   PubMed Web of Science ®Google Scholar
• Jian W, Xu Y, Edom RW, Weng N. (2011). Analysis of polar metabolites by hydrophilic interaction chromatography–MS/MS. Bioanalysis 3:899–912.
   PubMed Web of Science ®Google Scholar
• Niazi M, Skrtic S, Ruth M, Holmberg AA. (2011). Pharmacokinetic profile of lesogaberan (AZD3355) in healthy subjects: A novel GABA(B)-receptor agonist reflux inhibitor. Drugs R D 11:77–83.
   Google Scholar
• Smith DA, Obach RS. (2009). Metabolites in safety testing (MIST): Considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267–279.
   PubMed Web of Science ®Google Scholar
• Sun J, Dahan A, Amidon GL. (2010). Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: A double-targeted prodrug approach. J Med Chem 53:624–632.
   PubMed Web of Science ®Google Scholar
• Walker JB. (1979). Creatine: Biosynthesis, regulation, and function. Adv Enzymol Relat Areas Mol Biol 50:177–242.
   PubMedGoogle Scholar